NorLevo® is an oral emergency contraceptive, which is taken within 72 hours after unprotected sexual intercourse or contraceptive failure to prevent unwanted pregnancy.
Its active ingredient, levonorgestrel (synthetic progestagen), is listed as an essential drug by WHO.
- 28 Jan 2014
Sosei announces the transfer of Japan marketing authorization for NorLevo TABLETS 0.75mg to ASKA Pharmaceuticals
- 2 Jul 2012
Sosei announces successful completion of Phase I study for SO-1105 for the treatment of oropharyngeal candidiasis
- 8 Mar 2012
Sosei Announces Initiation of Phase I study for SO-1105
- 23 May 2011
Sosei to Launch NorLevo TABLETS 0.75mg (Emergency Contraceptive Pill) in Japan
For information related to NorLevo® please use the below contact details.
|Contact||ASKA Pharmaceutical Co. Ltd.
|Hours||Monday to Friday 9am – 5.30pm (except holidays)|
In Australia, Sosei licensed marketing rights for NorLevo® to Sandoz Pty Ltd. in December 2005.